Relay Therapeutics Inc. (RLAY): Price and Financial Metrics
RLAY Price/Volume Stats
| Current price | $6.08 | 52-week high | $13.32 |
| Prev. close | $5.95 | 52-week low | $5.78 |
| Day low | $6.08 | Volume | 180 |
| Day high | $6.08 | Avg. volume | 1,132,879 |
| 50-day MA | $8.48 | Dividend yield | N/A |
| 200-day MA | $9.36 | Market Cap | 797.57M |
RLAY Stock Price Chart Interactive Chart >
Relay Therapeutics Inc. (RLAY) Company Bio
Relay Therapeutics, Inc. is a clinical-stage precision medicines company. It focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.
Latest RLAY News From Around the Web
Below are the latest news stories about RELAY THERAPEUTICS INC that investors may wish to consider to help them evaluate RLAY as an investment opportunity.
Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In NovemberThe AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions. |
Wall Street Analysts Think Relay Therapeutics, Inc. (RLAY) Could Surge 189.21%: Read This Before Placing a BetThe mean of analysts' price targets for Relay Therapeutics, Inc. (RLAY) points to an 189.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Wall Street Analysts See a 202.33% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?The consensus price target hints at a 202.3% upside potential for Relay Therapeutics, Inc. (RLAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
AI Alert: 3 Healthcare Stocks That Are Investing in Artificial IntelligenceWe’re still in the initial stages of a massively disruptive artificial intelligence (AI) boom that's greatly impacting healthcare. |
Relay Therapeutics to Participate in Stifel 2023 Healthcare ConferenceCAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) today announced that management will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023 at 1:50 p.m. ET. The fireside chat will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webc |
RLAY Price Returns
| 1-mo | -21.95% |
| 3-mo | -38.27% |
| 6-mo | -3.95% |
| 1-year | -49.54% |
| 3-year | -81.76% |
| 5-year | N/A |
| YTD | -44.78% |
| 2023 | -26.31% |
| 2022 | -51.35% |
| 2021 | -26.11% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...